Ad C. van Nuenen

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

Meike H. van der Ree, J. Marleen de Vree, F. Stelma et al. · The Lancet · 2017 · 259 citations

Phase 1B, Hepatology, Hepatitis C +7

Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection

Evelien M. Bunnik, Linaida Pisas, Ad C. van Nuenen et al. · Journal of Virology · 2008 · 179 citations · Full text

Humoral Response, Immunology, Immunotherapy +18

Identification of <i>Campylobacter jejuni</i> Promoter Sequences

Marc M. S. M. Wösten, Miranda Boeve, M. KOOT et al. · Journal of Bacteriology · 1998 · 151 citations · Full text

Biosynthesis, Promoter Activity, Protein Expression +14

Miravirsen dosing in chronic hepatitis C patients results in decreased micro<scp>RNA</scp>‐122 levels without affecting other micro<scp>RNA</scp>s in plasma

Meike H. van der Ree, Ad C. van Nuenen, Joep de Bruijne et al. · Alimentary Pharmacology & Therapeutics · 2015 · 149 citations · Full text

Infection and transmission of SARS‐CoV‐2 depend on heparan sulfate proteoglycans

Marta Bermejo‐Jambrina, Julia Eder, Tanja M. Kaptein et al. · The EMBO Journal · 2021 · 82 citations · Full text